thioctic acid has been researched along with Polycystic Ovarian Syndrome in 20 studies
Thioctic Acid: An octanoic acid bridged with two sulfurs so that it is sometimes also called a pentanoic acid in some naming schemes. It is biosynthesized by cleavage of LINOLEIC ACID and is a coenzyme of oxoglutarate dehydrogenase (KETOGLUTARATE DEHYDROGENASE COMPLEX). It is used in DIETARY SUPPLEMENTS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this retrospective study was to evaluate the effects of a long-term treatment with α-lipoic acid (ALA) combined with myo-inositol (MI) on clinical and metabolic features of women with polycystic ovary syndrome (PCOS)." | 7.96 | Long-term treatment with α-lipoic acid and myo-inositol positively affects clinical and metabolic features of polycystic ovary syndrome. ( Fidecicchi, T; Fruzzetti, F; Gambacciani, M; Palla, G, 2020) |
| "To evaluate the effects of the combination of d-chiro inositol and alpha lipoic acid on menstrual cycles and insulin sensitivity in women with polycystic ovary syndrome (PCOS)." | 7.91 | Treatment with d-chiro-inositol and alpha lipoic acid in the management of polycystic ovary syndrome. ( Canu, A; Capozzi, A; Fruzzetti, F; Lello, S, 2019) |
| "The aim of our study was to investigate the effects of a combined treatment with alpha-lipoic acid (ALA) and myoinositol (MYO) on clinical, endocrine and metabolic features of women affected by polycystic ovary syndrome (PCOS)." | 7.85 | Myoinositol combined with alpha-lipoic acid may improve the clinical and endocrine features of polycystic ovary syndrome through an insulin-independent action. ( Apa, R; De Cicco, S; Della Casa, S; Di Florio, C; Immediata, V; Lanzone, A; Policola, C; Romualdi, D; Scarinci, E; Tagliaferri, V; Tropea, A, 2017) |
| "Polycystic ovary syndrome is characterized by several endocrine impairments, insulin resistance and hyperinsulinemia." | 5.51 | Differential insulin response to oral glucose tolerance test (OGTT) in overweight/obese polycystic ovary syndrome patients undergoing to myo-inositol (MYO), alpha lipoic acid (ALA), or combination of both. ( Genazzani, AD; Marchini, F; Napolitano, A; Petrillo, T; Prati, A; Simoncini, T, 2019) |
| "This new myo-inositol, monacolin K and lipoic acid association contains appropriate substances to contrast various etiopathogenic elements responsible for the onset of PCOS and the symptoms of hyperandrogenism and dyslipidemia related to it." | 5.20 | Polycystic ovary syndrome (PCOS) and hyperandrogenism: the role of a new natural association. ( Cappelli, V; De Leo, V; Di Sabatino, A; Massaro, MG; Morgante, G, 2015) |
| "The combination of pioglitazone and α-lipoic acid has a significantly improving effect on BMI, body weight, oxidative stress levels, lipid metabolism, and menstrual status." | 4.31 | Beneficial effects of pioglitazone and α-lipoic acid in patients with polycystic ovaries syndrome. ( Hu, H; Liu, YY; Pei, Y; Sun, M; Wang, B; Wang, ZL; Zheng, J; Zhou, TT, 2023) |
| "The aim of this retrospective study was to evaluate the effects of a long-term treatment with α-lipoic acid (ALA) combined with myo-inositol (MI) on clinical and metabolic features of women with polycystic ovary syndrome (PCOS)." | 3.96 | Long-term treatment with α-lipoic acid and myo-inositol positively affects clinical and metabolic features of polycystic ovary syndrome. ( Fidecicchi, T; Fruzzetti, F; Gambacciani, M; Palla, G, 2020) |
| "To evaluate the effects of the combination of d-chiro inositol and alpha lipoic acid on menstrual cycles and insulin sensitivity in women with polycystic ovary syndrome (PCOS)." | 3.91 | Treatment with d-chiro-inositol and alpha lipoic acid in the management of polycystic ovary syndrome. ( Canu, A; Capozzi, A; Fruzzetti, F; Lello, S, 2019) |
| "The aim of our study was to investigate the effects of a combined treatment with alpha-lipoic acid (ALA) and myoinositol (MYO) on clinical, endocrine and metabolic features of women affected by polycystic ovary syndrome (PCOS)." | 3.85 | Myoinositol combined with alpha-lipoic acid may improve the clinical and endocrine features of polycystic ovary syndrome through an insulin-independent action. ( Apa, R; De Cicco, S; Della Casa, S; Di Florio, C; Immediata, V; Lanzone, A; Policola, C; Romualdi, D; Scarinci, E; Tagliaferri, V; Tropea, A, 2017) |
| "To evaluate the effects of the combination of d-chiro-inositol (DCI) and alpha lipoic acid on menses and metabolic disorders in women with polycystic ovary syndrome (PCOS)." | 3.81 | d-chiro-Inositol and alpha lipoic acid treatment of metabolic and menses disorders in women with PCOS. ( Bartolo, M; Caruso, S; Cianci, A; Falduzzi, C; Fichera, M; Panella, M, 2015) |
| "Insulin resistance is becoming an increasingly studied target for therapy, most evidence stemming from the time-honored metformin use." | 2.66 | Current treatment for polycystic ovary syndrome: focus on adolescence. ( Catellani, C; Cirillo, F; Dauriz, M; Lazzeroni, P; Moghetti, P; Sartori, C; Street, ME, 2020) |
| "Polycystic ovary syndrome is associated with reproductive and metabolic dysfunction; in fact, treatment aims in PCOS focus on optimizing healthy weight, improving underlying hormonal disturbances, preventing future reproductive and metabolic complications, and improving quality of life." | 1.72 | Effects of a combination of resveratrol and alpha-lipoic acid on body weight and adipose composition in women with PCOS: a preliminary pilot study. ( Dellino, M; Lupica, G; Malvasi, A; Mynbaev, O; Spyropoulou, K; Tinelli, A; Vimercati, A, 2022) |
| "Polycystic ovary syndrome is characterized by several endocrine impairments, insulin resistance and hyperinsulinemia." | 1.51 | Differential insulin response to oral glucose tolerance test (OGTT) in overweight/obese polycystic ovary syndrome patients undergoing to myo-inositol (MYO), alpha lipoic acid (ALA), or combination of both. ( Genazzani, AD; Marchini, F; Napolitano, A; Petrillo, T; Prati, A; Simoncini, T, 2019) |
| "ALA integrative administration at a low dosage as 400 mg daily improved the metabolic impairment of all PCOS patients especially in those PCOS with familiar diabetes who have a higher grade of risk of NAFLD and predisposition to diabetes." | 1.48 | Modulatory effects of alpha-lipoic acid (ALA) administration on insulin sensitivity in obese PCOS patients. ( Della Casa, D; Despini, G; Genazzani, AD; Manzo, A; Napolitano, A; Prati, A; Shefer, K; Simoncini, T, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (45.00) | 24.3611 |
| 2020's | 11 (55.00) | 2.80 |
| Authors | Studies |
|---|---|
| Scarinci, E | 2 |
| Notaristefano, G | 1 |
| Tropea, A | 2 |
| Fabozzi, SM | 1 |
| Alesiani, O | 1 |
| Meucci, E | 1 |
| Silvestrini, A | 1 |
| Cintoni, M | 1 |
| Diterlizzi, A | 1 |
| Lanzone, A | 2 |
| Apa, R | 2 |
| Laganà, AS | 1 |
| Monti, N | 1 |
| Fedeli, V | 1 |
| Gullo, G | 1 |
| Bizzarri, M | 1 |
| Malvasi, A | 1 |
| Tinelli, A | 1 |
| Lupica, G | 1 |
| Vimercati, A | 1 |
| Spyropoulou, K | 1 |
| Dellino, M | 1 |
| Mynbaev, O | 1 |
| Capece, U | 1 |
| Moffa, S | 1 |
| Improta, I | 1 |
| Di Giuseppe, G | 1 |
| Nista, EC | 1 |
| Cefalo, CMA | 1 |
| Cinti, F | 1 |
| Pontecorvi, A | 1 |
| Gasbarrini, A | 1 |
| Giaccari, A | 1 |
| Mezza, T | 1 |
| Guarano, A | 1 |
| Capozzi, A | 2 |
| Cristodoro, M | 1 |
| Di Simone, N | 1 |
| Lello, S | 2 |
| Pei, Y | 1 |
| Liu, YY | 1 |
| Sun, M | 1 |
| Zheng, J | 1 |
| Zhou, TT | 1 |
| Wang, B | 1 |
| Hu, H | 1 |
| Wang, ZL | 1 |
| Aslanipour, B | 1 |
| Alan, M | 1 |
| Demir, I | 1 |
| Artini, PG | 1 |
| Obino, MER | 1 |
| Micelli, E | 1 |
| Malacarne, E | 1 |
| Vacca, C | 1 |
| Papini, F | 1 |
| Cela, V | 1 |
| Street, ME | 1 |
| Cirillo, F | 1 |
| Catellani, C | 1 |
| Dauriz, M | 1 |
| Lazzeroni, P | 1 |
| Sartori, C | 1 |
| Moghetti, P | 1 |
| Lei, W | 1 |
| Gao, Y | 1 |
| Hu, S | 1 |
| Liu, D | 1 |
| Chen, Q | 1 |
| De Cicco, S | 1 |
| Immediata, V | 1 |
| Romualdi, D | 1 |
| Policola, C | 1 |
| Di Florio, C | 1 |
| Tagliaferri, V | 1 |
| Della Casa, S | 1 |
| Genazzani, AD | 2 |
| Shefer, K | 1 |
| Della Casa, D | 1 |
| Prati, A | 2 |
| Napolitano, A | 2 |
| Manzo, A | 1 |
| Despini, G | 1 |
| Simoncini, T | 2 |
| Di Tucci, C | 1 |
| Di Feliciantonio, M | 1 |
| Vena, F | 1 |
| Capone, C | 1 |
| Schiavi, MC | 1 |
| Pietrangeli, D | 1 |
| Muzii, L | 1 |
| Benedetti Panici, P | 1 |
| Fruzzetti, F | 2 |
| Canu, A | 1 |
| Marchini, F | 1 |
| Petrillo, T | 1 |
| Fidecicchi, T | 1 |
| Palla, G | 1 |
| Gambacciani, M | 1 |
| Cappelli, V | 2 |
| Di Sabatino, A | 2 |
| Musacchio, MC | 1 |
| De Leo, V | 2 |
| Cianci, A | 1 |
| Panella, M | 1 |
| Fichera, M | 1 |
| Falduzzi, C | 1 |
| Bartolo, M | 1 |
| Caruso, S | 1 |
| Morgante, G | 1 |
| Massaro, MG | 1 |
| Masharani, U | 1 |
| Gjerde, C | 1 |
| Evans, JL | 1 |
| Youngren, JF | 1 |
| Goldfine, ID | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Alpha Lipoic Acid and Polycystic Ovary Syndrome[NCT00505427] | Phase 1 | 22 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| Effects of Inositol Alone or Associated With Alpha-lipoic Acid in Polycystic Ovary Syndrome Treatment[NCT04881851] | 90 participants (Anticipated) | Interventional | 2015-05-07 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for thioctic acid and Polycystic Ovarian Syndrome
| Article | Year |
|---|---|
Alpha-Lipoic Acid and Glucose Metabolism: A Comprehensive Update on Biochemical and Therapeutic Features.
Topics: Antioxidants; Autoimmune Diseases; Diabetic Neuropathies; Female; Glucose; Humans; Insulin Resistanc | 2022 |
Alpha Lipoic Acid Efficacy in PCOS Treatment: What Is the Truth?
Topics: Antioxidants; Diabetes Mellitus, Type 2; Female; Humans; Inositol; Insulin; Insulin Resistance; Metf | 2023 |
Current treatment for polycystic ovary syndrome: focus on adolescence.
Topics: Adolescent; Contraceptives, Oral, Hormonal; Female; Gene-Environment Interaction; Humans; Hypoglycem | 2020 |
Alpha lipoic acid in obstetrics and gynecology.
Topics: Abortion, Threatened; Antioxidants; Dietary Supplements; Female; Gynecology; Humans; Obstetrics; Oxi | 2018 |
2 trials available for thioctic acid and Polycystic Ovarian Syndrome
| Article | Year |
|---|---|
[Evaluation of a new association between insulin-sensitizers and α-lipoic acid in obese women affected by PCOS].
Topics: Adult; Antioxidants; Blood Glucose; Body Mass Index; Drug Therapy, Combination; Electron Transport; | 2013 |
Polycystic ovary syndrome (PCOS) and hyperandrogenism: the role of a new natural association.
Topics: Adult; Antioxidants; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyslipidemias; Fem | 2015 |
14 other studies available for thioctic acid and Polycystic Ovarian Syndrome
| Article | Year |
|---|---|
Insulin-sensitizing effect and antioxidant action of alpha lipoic acid in oligomenorrheic women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Antioxidants; Female; Humans; Insulin; Insulin, Regular, Human; Pilot Projects; P | 2023 |
Does Alpha-lipoic acid improve effects on polycystic ovary syndrome?
Topics: Female; Humans; Inositol; Insulin; Insulin Resistance; Polycystic Ovary Syndrome; Thioctic Acid | 2022 |
Effects of a combination of resveratrol and alpha-lipoic acid on body weight and adipose composition in women with PCOS: a preliminary pilot study.
Topics: Female; Folic Acid; Humans; Overweight; Pilot Projects; Polycystic Ovary Syndrome; Quality of Life; | 2022 |
Beneficial effects of pioglitazone and α-lipoic acid in patients with polycystic ovaries syndrome.
Topics: Animals; Body Weight; Female; Humans; Insulin; Mice; Pioglitazone; Polycystic Ovary Syndrome; Thioct | 2023 |
Decreased levels of liver-expressed antimicrobial peptide-2 and ghrelin are related to insulin resistance in women with polycystic ovary syndrome.
Topics: Adult; Antimicrobial Cationic Peptides; Blood Glucose; Blood Proteins; C-Reactive Protein; Case-Cont | 2020 |
Effect of d-chiro-inositol and alpha-lipoic acid combination on COH outcomes in overweight/obese PCOS women.
Topics: Adult; Drug Therapy, Combination; Female; Fertility Agents, Female; Fertilization in Vitro; Gonadotr | 2020 |
Effects of inositol and alpha lipoic acid combination for polycystic ovary syndrome: A protocol for systematic review and meta-analysis.
Topics: Drug Therapy, Combination; Female; Humans; Inositol; Meta-Analysis as Topic; Polycystic Ovary Syndro | 2020 |
Myoinositol combined with alpha-lipoic acid may improve the clinical and endocrine features of polycystic ovary syndrome through an insulin-independent action.
Topics: Adolescent; Adult; Androstenedione; Body Mass Index; Dehydroepiandrosterone Sulfate; Drug Therapy, C | 2017 |
Modulatory effects of alpha-lipoic acid (ALA) administration on insulin sensitivity in obese PCOS patients.
Topics: Adult; Antioxidants; Body Mass Index; Diabetes Mellitus; Female; Follow-Up Studies; Humans; Insulin | 2018 |
Treatment with d-chiro-inositol and alpha lipoic acid in the management of polycystic ovary syndrome.
Topics: Adolescent; Adult; Body Mass Index; Body Weight; Drug Therapy, Combination; Estradiol; Female; Folli | 2019 |
Differential insulin response to oral glucose tolerance test (OGTT) in overweight/obese polycystic ovary syndrome patients undergoing to myo-inositol (MYO), alpha lipoic acid (ALA), or combination of both.
Topics: Adult; Androstenedione; Drug Therapy, Combination; Estradiol; Female; Follicle Stimulating Hormone; | 2019 |
Long-term treatment with α-lipoic acid and myo-inositol positively affects clinical and metabolic features of polycystic ovary syndrome.
Topics: Adult; Body Mass Index; Female; Hirsutism; Humans; Inositol; Insulin Resistance; Organ Size; Ovary; | 2020 |
d-chiro-Inositol and alpha lipoic acid treatment of metabolic and menses disorders in women with PCOS.
Topics: Adolescent; Adult; Drug Therapy, Combination; Female; Humans; Inositol; Menstruation Disturbances; M | 2015 |
Effects of controlled-release alpha lipoic acid in lean, nondiabetic patients with polycystic ovary syndrome.
Topics: Adult; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Delayed-Acti | 2010 |
Effects of controlled-release alpha lipoic acid in lean, nondiabetic patients with polycystic ovary syndrome.
Topics: Adult; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Delayed-Acti | 2010 |
Effects of controlled-release alpha lipoic acid in lean, nondiabetic patients with polycystic ovary syndrome.
Topics: Adult; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Delayed-Acti | 2010 |
Effects of controlled-release alpha lipoic acid in lean, nondiabetic patients with polycystic ovary syndrome.
Topics: Adult; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Delayed-Acti | 2010 |